Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Redhill Biopharma 2/07 0,812 USD
-2,13% 		-2,13%
vlag Regeneron Pharmaceuticals, Inc. 2/07 654,270 USD
+4,73% 		+4,73%
vlag Regenxbio Inc 2/07 13,280 USD
+1,45% 		+1,45%
vlag Relay Therapeutics Inc 2/07 18,650 USD
+5,01% 		+5,01%
vlag Repligen Corp. 2/07 142,400 USD
+2,45% 		+2,45%
vlag Replimune Group Inc 2/07 11,580 USD
+3,21% 		+3,21%
vlag Resverlogix Corp. 2/07 0,090 CAD
0,00% 		0,00%
vlag Rhythm Pharmaceuticals Inc. 2/07 114,170 USD
+3,41% 		+3,41%
vlag Rigel Pharmaceuticals 2/07 38,720 USD
+1,12% 		+1,12%
vlag Rocket Pharmaceuticals Inc 2/07 3,840 USD
+9,09% 		+9,09%
vlag Rubicon Organics Inc 3/07 0,455 CAD
+1,11% 		+1,11%

Nieuws over “Biotechnologie”

04:00 · ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

04:00 · ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

2/07 · Monthly information on share capital and company voting rights · Persbericht

2/07 · Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026 · Persbericht

2/07 · GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH · Persbericht

2/07 · Declaration voting rights - June 30,2026 · Persbericht

2/07 · ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 · Persbericht

1/07 · Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia · Persbericht

1/07 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1/07 · ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1/07 · ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline · Persbericht

1/07 · Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test · Persbericht

1/07 · Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer · Persbericht

1/07 · ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit · Persbericht

30/06 · Halozyme Appoints David Ramsay as President Drug Delivery · Persbericht

30/06 · Acquisition of Own Shares · Persbericht

30/06 · Inkoop van eigen aandelen · Persbericht

30/06 · A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs · Persbericht

30/06 · COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT · Persbericht

30/06 · $ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action · Persbericht

30/06 · Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics · Persbericht

Mijn selecties